Filter Results:
(1,244)
Show Results For
- All HBS Web
(1,244)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Show Results For
- All HBS Web
(1,244)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
- May 2005
- Case
Merck: Conflict and Change
Tracks Merck's efforts to adapt to changes in the pharmaceutical industry. Key challenges include adapting Merck's internally focused, science-led culture to a more open environment, where marketing performance has become increasingly important. Examines Merck's... View Details
Keywords: Organizational Change and Adaptation; Organizational Culture; Conflict and Resolution; Pharmaceutical Industry
Gilbert, Clark, and Ratna G. Sarkar. "Merck: Conflict and Change." Harvard Business School Case 805-079, May 2005.
- January 2001
- Case
Merck Global Health Initiatives (A)
By: James E. Austin, Diana Barrett and James Weber
The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,... View Details
Keywords: Programs; Philanthropy and Charitable Giving; Health Disorders; Health Care and Treatment; Private Sector; Public Sector; Alliances; Problems and Challenges; Pharmaceutical Industry; Botswana
Austin, James E., Diana Barrett, and James Weber. "Merck Global Health Initiatives (A)." Harvard Business School Case 301-088, January 2001.
- 06 Jul 2017
- Working Paper Summaries
Do All Your Detailing Efforts Pay Off? Dynamic Panel Data Methods Revisited
- Video
Dr. Silvia Gold
Dr. Silvia Gold, President of the Mundo Sano Foundation and co-founder of Grupo Insud, explains how patent expiration is important for innovation, recounting that her company has always won against large Western pharmaceutical companies that have sought legal action... View Details
- April 2010
- Case
Metabical: Pricing, Packaging, and Demand Forecasting Recommendations for a New Weight Loss Drug
By: John A. Quelch and Heather Beckham
Metabical is a new weight loss drug from Cambridge Sciences Pharmaceuticals intended for moderately overweight individuals. In anticipation of final FDA approval, the senior director of marketing, Barbara Printup, prepares for the product launch and must make several... View Details
Keywords: Return On Investment; Forecasting; Pricing Policies; Demand Planning; Marketing Strategy; Price; Consumer Behavior; Investment Return; Forecasting and Prediction; Product Launch; Planning; Brands and Branding; Pharmaceutical Industry
Quelch, John A., and Heather Beckham. "Metabical: Pricing, Packaging, and Demand Forecasting Recommendations for a New Weight Loss Drug." Harvard Business School Brief Case 104-183, April 2010.
- August 1990 (Revised January 1992)
- Case
Eli Lilly and Co. (B): Europe
Examines the challenges facing the company in light of the changing economic, regulatory, and competitive environment in the European pharmaceutical industry. Examines the steps taken by the company adapting to this changing situation as part of a total globalization... View Details
Keywords: Change Management; Economics; Global Strategy; Business or Company Management; Growth and Development Strategy; Adaptation; Competition; Pharmaceutical Industry; Europe
Yoshino, Michael Y. "Eli Lilly and Co. (B): Europe." Harvard Business School Case 391-033, August 1990. (Revised January 1992.)
- January 1995 (Revised November 2021)
- Case
Portfolio Planning at Ciba-Geigy and the Newport Investment Proposal
By: David J. Collis and Elizabeth Wynne Johnson
Covers the history of portfolio planning at CIBA-GEIGY, a leading Swiss chemical and pharmaceutical company, beginning with the introduction of the process in the mid-1980s. The discussion extends to the application of portfolio planning techniques to a specific... View Details
Keywords: Investment Portfolio; Corporate Strategy; Factories, Labs, and Plants; Chemicals; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
Collis, David J., and Elizabeth Wynne Johnson. "Portfolio Planning at Ciba-Geigy and the Newport Investment Proposal." Harvard Business School Case 795-040, January 1995. (Revised November 2021.)
- 22 Feb 2021
- Working Paper Summaries
Private and Social Returns to R&D: Drug Development and Demographics
- Research Summary
Entry deterrence via strategic litigation
This paper analyzes the use of litigation by incumbents to deter entry by new firms. Specifically, I look at a context where incumbent firms own patents that confer a limited monopoly period in the market. In the US pharmaceutical industry, regulation provides for... View Details
- October 2016 (Revised February 2017)
- Teaching Note
Alvogen
By: Daniel Isenberg, William R. Kerr and Alexis Brownell
Alvogen is an Icelandic pharmaceutical company that makes and sells generic drugs. Founder and CEO Robert Wessman is deciding whether to take on private equity investors willing to buy out all shareholders, merge with a large and publicly-traded US pharmaceutical... View Details
- September 1995
- Case
Ares-Serono
By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details
Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland; Europe
Yoshino, Michael Y., Jean-Pierre Jeannet, and Carin-Isabel Knoop. "Ares-Serono." Harvard Business School Case 396-035, September 1995.
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (B)
ALZA, a drug delivery company, must decide what and for whom to manufacture. In the past, it has licensed to pharmaceutical companies its patented system for the slow release of drugs into the human system. Therefore the company has little experience in choice of drug... View Details
Keywords: Experience and Expertise; Decision Choices and Conditions; Patents; Production; Pharmaceutical Industry; Pharmaceutical Industry
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (B)." Harvard Business School Supplement 694-020, September 1993.
- 22 Feb 2011
- News
Why Innovation Is So Hard in Health Care - and How to Do It Anyway
- October 2002
- Case
A Father's Love: Novazyme Pharmaceuticals, Inc.
By: Richard M.J. Bohmer and Bradley Campbell
John Crowley, CEO of Novazyme Pharmaceuticals, a start-up biotechnology firm developing an orphan drug to treat a rare lysosomal storage disorder from which his children suffer, must choose between a partnership and a buyout to have sufficient funds and support to get... View Details
Keywords: Technological Innovation; Business Startups; Partners and Partnerships; Financing and Loans; Governing Rules, Regulations, and Reforms; Sales; Price; Product Development; Motivation and Incentives; Decision Choices and Conditions; Pharmaceutical Industry; Pharmaceutical Industry
Bohmer, Richard M.J., and Bradley Campbell. "A Father's Love: Novazyme Pharmaceuticals, Inc." Harvard Business School Case 603-048, October 2002.
- 22 Sep 2015
- News
Should Bank of America's CEO also be the chairman?
- 17 May 2016
- News
What Is The Most Important Innovation in American History?
- 15 Feb 2011
- News
Who will blink in Genzyme, Sanofi price talks?
- September 2023 (Revised April 2024)
- Case
Atomwise: Strategic Opportunities in AI for Pharma
By: Satish Tadikonda
Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details
Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry
Tadikonda, Satish. "Atomwise: Strategic Opportunities in AI for Pharma." Harvard Business School Case 824-043, September 2023. (Revised April 2024.)
- February 2009 (Revised December 2009)
- Case
Merck: Global Health and Access to Medicines
By: V. Kasturi Rangan and Katharine Lee
The case describes the effort of Merck, a global leader in pharmaceuticals, in making available its medicines to the poor. The challenge for the company (or for that matter, any pharmaceutical company) is how to integrate its business strategy with its corporate social... View Details
Keywords: Globalized Firms and Management; Health Care and Treatment; Emerging Markets; Corporate Social Responsibility and Impact; Poverty; Business Strategy; Pharmaceutical Industry
Rangan, V. Kasturi, and Katharine Lee. "Merck: Global Health and Access to Medicines." Harvard Business School Case 509-048, February 2009. (Revised December 2009.)